Bevacizumab/nivolumabThrombotic microangiopathy and hypertension: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1949卷 / 1期

关键词：

D O I：

10.1007/s40278-023-36084-0

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：104 / 104

相关论文

共 50 条

[1] Bevacizumab/nivolumabThrombotic microangiopathy and acute tubulointerstitial nephritis
[J]. Reactions Weekly, 2023, 1985 (1) : 116 - 116
[2] NivolumabThrombotic microangiopathy: case report
[J]. Reactions Weekly, 2021, 1868 (1) : 335 - 335
[3] Ipilimumab/nivolumabThrombotic microangiopathy and diarrhoea: case report
[J]. Reactions Weekly, 2021, 1869 (1) : 196 - 196
[4] SunitinibThrombotic microangiopathy, cerebral infarction and hypertension: 2 case reports
[J]. Reactions Weekly, 2023, 1979 (1) : 438 - 438
[5] Bevacizumab/octreotideDiarrhoea, hypertension and epistaxis: 2 case reports
[J]. Reactions Weekly, 2020, 1792 (1) : 54 - 54
[6] Bevacizumab/doxorubicin/gemcitabineGlomerular microangiopathy, acute thrombotic microangiopathy and chronic thrombotic microangiopathy : 22 case reports
[J]. Reactions Weekly, 2020, 1805 (1) : 64 - 64
[7] BevacizumabThrombotic microangiopathy, hypertension and proteinuria: 6 case reports
[J]. Reactions Weekly, 2008, 1194-1195 (1) : 8 - 8
[8] Bevacizumab/doxorubicinMyelosuppression and hypertension: 3 case reports
[J]. Reactions Weekly, 2022, 1888 (1) : 103 - 103
[9] Bevacizumab/ranibizumabOcular hypertension: 10 case reports
[J]. Reactions Weekly, 2021, 1877 (1) : 71 - 71
[10] Bevacizumab/gemcitabine/sorafenibKidney disease and thrombotic microangiopathy: 5 case reports
[J]. Reactions Weekly, 2014, 1520 (1) : 40 - 40

← 1 2 3 4 5 →